Shaanxi Yatai Testing and Evaluation Co., Ltd. announced that it will receive CNY 25 million in an equity round of funding on April 3, 2023. The transaction will include participation from returning investor, Shaanxi Meibang Pharmaceutical Group Co., Ltd. The transaction has been approved by the board of directors of the company at its 19th session of the company?s 2nd directorate and the 15th session of the company?s 2nd supervisory board. Post the closing, the registered capital of the company will increase from CNY 50 million to CNY 75 million.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.58 CNY | -1.53% |
|
-0.69% | -35.49% |
1st Jan change | Capi. | |
---|---|---|
-35.49% | 219M | |
-14.24% | 3.1B | |
-45.71% | 1.46B | |
-16.56% | 1.44B | |
-22.28% | 1.42B | |
-35.59% | 1.38B | |
-13.03% | 1.19B | |
-13.92% | 978M | |
+59.89% | 938M | |
-35.17% | 856M |
- Stock Market
- Equities
- 605033 Stock
- News Shaanxi Meibang Pharmaceutical Group Co., Ltd.
- Shaanxi Yatai Testing and Evaluation Co., Ltd. announced that it expects to receive CNY 25 million in funding from Shaanxi Meibang Pharmaceutical Group Co., Ltd.